Individualization of immediate posttransplant immunosuppression. The value of antilymphocyte globulin in patients with delayed graft function.
In patients with delayed graft function (DGF), the use of cyclosporine (CsA) has been reported to prolong DGF, increase the number of required dialyses, increase the duration of hospitalization, and be associated with decreased graft survival. Routine postoperative antilymphocyte globulin (ALG) use has been advocated, but ALG is associated with increased viral infection. We studied outcome of individualization of immunosuppression. Between 11/84 and 8/86, first-cadaver transplant recipients whose serum creatinine (Cr) fell greater than or equal to 30% in the first 24 hr (immediate function) were started on CsA and prednisone (P) (group 1, n = 26). The remainder were randomized to P and azathioprine (group 2, n = 32) or P and ALG (group 3, n = 26), and switched to CsA when serum Cr fell greater than 30% (minimum 5 days ALG for the ALG group). P taper was the same in all groups. Patients with DGF (groups 2 and 3) had longer preservation time and higher peak PRA (P less than .05) than group 1. Groups were otherwise equivalent. One and 2-year patient survival was 96% (3 cardiovascular deaths; all with functioning grafts). One-year graft survival was 87% for group 1, 87% for group 2, and 82% for group 3(NS). In patients requiring dialysis, mean day off dialysis was 12 +/- 3 in both groups 2 and 3. Mean hospital stay was 12.5 +/- 1.3 days for group 1, 21.6 +/- 2.1 days for group 2 (P less than .05 vs. 1 & 3), and 14.5 +/- 1.2 days for group 3 (NS vs. 1). The increased hospital stay for group 2 patients was mainly due to increased in-hospital rejections: 75% for group 2, (P less than .05 vs. group 1 [35%], and group 3 [11.5%]). In addition, more group 2 in-hospital 1st rejections were steroid resistant as compared to group 1; 46% group 1 patients have remained rejection free as compared to 0% group 2 (P less than .05 vs. 1 and 3) and 35% of group 3 (P less than .05 vs. 1 and 2). Mean serum creatinine at 6-12 months remained higher in patients with DGF (group 1 P less than .05 vs. 2 and 3). Rejection was the major cause of graft loss in all groups.(ABSTRACT TRUNCATED AT 400 WORDS)
Matas
A J
AJ
Department of Surgery, Montefiore Medical Center, New York 10467.
Tellis
V A
VA
Quinn
T A
TA
Glicklich
D
D
Soberman
R
R
Veith
F J
FJ
D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000032:analysis / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood*; D003524:Cyclosporins / Q000627:therapeutic use; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D016030:Kidney Transplantation; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011241:Prednisone / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D003524:Cyclosporins; D003404:Creatinine; D011241:Prednisone